Healius Needs Longer in Recovery Room -- Market Talk

Dow Jones

2025/08/25

0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that "sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing." Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

August 24, 2025 21:01 ET (01:01 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562229309"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562229309\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562229309?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 09:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562229309","market":"us","top_or_hot":-1,"title":"Healius Needs Longer in Recovery Room -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 24, 2025 21:01 ET (01:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healius Needs Longer in Recovery Room -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealius Needs Longer in Recovery Room -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-25 09:01</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 24, 2025 21:01 ET (01:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健護理服務","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562229309","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562229309","pubTimestamp":1756083660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","HLS.AU":"HEALIUS LTD","BK7509":"中概股","BK7501":"新冠治疗股"},"translate_title":"Healius需要在恢复室呆更长时间——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLS.AU":0.9},"content_text":"0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 24, 2025 21:01 ET (01:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}